AAAAAA

   
Results: 1-10 |
Results: 10
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors
Authors: Lichtner, RB Menrad, A Sommer, A Klar, U Schneider, MR
Citation: Rb. Lichtner et al., Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors, CANCER RES, 61(15), 2001, pp. 5790-5795
Insulin-like growth factor-binding protein-5 inhibits growth and induces differentiation of mouse osteosarcoma cells
Authors: Schneider, MR Zhou, R Hoeflich, A Krebs, O Schmidt, J Mohan, S Wolf, E Lahm, H
Citation: Mr. Schneider et al., Insulin-like growth factor-binding protein-5 inhibits growth and induces differentiation of mouse osteosarcoma cells, BIOC BIOP R, 288(2), 2001, pp. 435-442
Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins
Authors: Schneider, MR Lahm, H Wu, MY Hoeflich, A Wolf, E
Citation: Mr. Schneider et al., Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins, FASEB J, 14(5), 2000, pp. 629-640
Interleukin-6 stimulates clonogenic growth of primary and metastatic humancolon carcinoma cells
Authors: Schneider, MR Hoeflich, A Fischer, JR Wolf, E Sordat, B Lahm, H
Citation: Mr. Schneider et al., Interleukin-6 stimulates clonogenic growth of primary and metastatic humancolon carcinoma cells, CANCER LETT, 151(1), 2000, pp. 31-38
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
Authors: Wood, JM Bold, G Buchdunger, E Cozens, R Ferrari, S Frei, J Hofmann, F Mestan, J Mett, H O'Reilly, T Persohn, E Rosel, J Schnell, C Stover, D Theuer, A Towbin, H Wenger, F Woods-Cook, K Menrad, A Siemeister, G Schirner, M Thierauch, KH Schneider, MR Drevs, J Martiny-Baron, G Totzke, F Marme, D
Citation: Jm. Wood et al., PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, CANCER RES, 60(8), 2000, pp. 2178-2189
Inhibition of VEGF receptor tyrosine kinase
Authors: Siemeister, G Menrad, A Schirner, M Thierauch, KH Schneider, MR Martiny-Baron, G Marme, D Bold, G Rosel, J Wood, JM
Citation: G. Siemeister et al., Inhibition of VEGF receptor tyrosine kinase, ANGIOGENESIS IN HEALTH AND DISEASE, 2000, pp. 339-348
Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines
Authors: Lichtner, RB Parczyk, K Birchmeier, W Schneider, MR
Citation: Rb. Lichtner et al., Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines, J STEROID B, 71(5-6), 1999, pp. 181-189
From phenylaziridine to phenylkainoids. A formal synthesis of (+/-)-phenylkainic acid.
Authors: Schneider, MR Klotz, P Ungureanu, I Mann, A Wermuth, CG
Citation: Mr. Schneider et al., From phenylaziridine to phenylkainoids. A formal synthesis of (+/-)-phenylkainic acid., TETRAHEDR L, 40(20), 1999, pp. 3873-3876
Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Authors: Culig, Z Hoffmann, J Erdel, M Eder, IE Hobisch, A Hittmair, A Bartsch, G Utermann, G Schneider, MR Parczyk, K Klocker, H
Citation: Z. Culig et al., Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system, BR J CANC, 81(2), 1999, pp. 242-251
Synthesis of (+/-)-4-substituted pipecolinic acids from 4-alkylpyridines
Authors: Nazih, A Schneider, MR Mann, A
Citation: A. Nazih et al., Synthesis of (+/-)-4-substituted pipecolinic acids from 4-alkylpyridines, SYNLETT, (12), 1998, pp. 1337-1338
Risultati: 1-10 |